Highlights

  • Revenue surged 1,100% year-over-year, reflecting strong operational momentum and accelerating commercial traction.
  • More than 200 active projects underway, underscoring expanding client engagement and growing demand visibility.
  • Double-digit revenue growth projected for CY2026, signalling confidence in sustained top-line expansion and business scalability.
  • BU Share Price Structure Turns Positive After Falling Trendline Breakout.

Burcon NutraScience Corporation (TSX: BU) jumped about 15% after Stonegate Capital Partners updated its coverage. Q3 FY26 revenue reached $739,000, up 107% quarter-over-quarter, driven by protein sales at its Galesburg facility. The site marks Burcon’s shift to commercial-scale production, exiting CY2025 on target despite beginning the year without a production facility.

BU Stock Back in Focus After Strong Operational Update

Burcon NutraScience Corporation said staffing and infrastructure at Galesburg are fully in place, enabling incremental volume growth with limited added fixed costs and improving operating leverage. About 65–70% of expected growth is tied to existing customers, supported by over 200 active projects, reinforcing recurring revenue visibility.

Its expanding pea, canola, sunflower, and fava protein portfolio targets rising demand for high-protein foods, including GLP-1-driven diet trends. A $6.9M convertible debenture financing supports inventory and production growth. In 3Q26, revenue reached $0.74M (+1102% y/y), with improved cost discipline and guidance for double-digit growth and positive free cash flow in CY26.

Burcon NutraScience Tests Technical Floor — Ready for Recovery?

From a technical perspective, BU remains firmly positioned above its key rising trendline support, with the recent gap-up open further reinforcing an already constructive chart structure. The strong upside move, accompanied by elevated trading volumes, signals solid buying interest and improving bullish momentum. This rising trendline continues to serve as dynamic support, anchoring current price action. As long as BU sustains levels above this zone, the broader uptrend remains intact, maintaining a positive near-term bias and leaving room for additional upside extension.

Price action remains constructive, with the stock trading firmly above its 21-period Simple Moving Average (SMA), highlighting sustained near-term strength and improving trend structure. The 14-period Relative Strength Index (RSI), currently at 64.19, remains elevated, indicating building bullish momentum following the recent rebound. On the upside, immediate resistance is located near CAD 2.35, followed by a stronger barrier around CAD 2.50, where profit-taking activity or renewed selling pressure could emerge and temporarily limit further gains unless accompanied by strong volume confirmation.

Bulls Defend Key Level, Preserving Positive Structure

Burcon NutraScience Corporation (TSX: BU) appears positioned for continued upside, supported by accelerating commercialization, strong revenue growth, and improved operating leverage. Technically, the stock holds above key trendline support with rising momentum and constructive volume. While near-term resistance may trigger brief consolidation, the broader bias remains positive as long as support levels stay intact.